Jump to content

Acetaminophen

Unchecked
From Pharmacopedia
Acetaminophen (paracetamol, APAP)
Tylenol, Panadol (international), Ofirmev (IV); huge OTC presence

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Pharmacy
Starting dose
325-1000 mg PO every 4-6 hours as needed; maximum 4 g/d in healthy adults, 3 g/d in regular users or hepatic risk; pediatric 10-15 mg/kg every 4-6 hours
Preparations
325, 500, 650 mg tablets; 80, 160 mg chewables; 160 mg/5 mL pediatric liquid; 325 mg suppository; 1000 mg/100 mL IV (Ofirmev); fixed-dose combinations with opioids, decongestants, antihistamines
US FDA Max
4 g/d in healthy adults; 3 g/d conservative limit; 2 g/d in cirrhosis or chronic alcohol use
Common uses
Classification(s)
Pharmacology
Routes
Oral, rectal, IV
Onset
PO: 30-60 minutes; IV: minutes
Duration
4-6 hours
Half-life
1-3 hours (normal liver); markedly prolonged in overdose with glutathione depletion[1]
Bioavailability
~85-98% (oral)[1]
Pregnancy
Long the preferred analgesic-antipyretic in pregnancy; recent observational studies have raised speculative neurodevelopmental signals that remain under investigation.[citation needed]
Legal status
OTC and Rx-only (IV, combination products) in US
Purported mechanism
Acetaminophen's analgesic and antipyretic actions are incompletely characterized; central COX inhibition (particularly the COX-2 splice variant sometimes called COX-3, and inhibition of arachidonic acid pathways in CNS at low peroxide concentrations) is the leading hypothesis, with possible contribution from descending serotonergic pathways and TRPV1 modulation by the AM404 metabolite.0 The absence of meaningful peripheral cyclooxygenase inhibition explains the lack of antiplatelet and anti-inflammatory effect compared with NSAIDs, and the gastroprotective profile. Dose-dependent hepatotoxicity via the CYP2E1 metabolite N-acetyl-p-benzoquinone imine (NAPQI) once glutathione is depleted; N-acetylcysteine is the antidote and is most effective within 8-10 hours of overdose[1].
Pharmacopedia is intended for reference. Nothing here is advice. In an emergency call 911; US Poison Control 1-800-222-1222. See the full disclaimer.

Overdose and toxicity

[edit | edit source]

For a single acute ingestion at a known time, the Rumack-Matthew nomogram guides whether to treat: a serum acetaminophen concentration is drawn no earlier than 4 hours after ingestion and plotted against time.[2] In the United States the treatment line begins at 150 micrograms/mL at 4 hours (set 25% below Rumack and Matthew's original 200 micrograms/mL line, the FDA-adopted treatment threshold); a level on or above the line indicates N-acetylcysteine, a level below it does not.[3] The nomogram does NOT apply to chronic or repeated (staggered) ingestion, an unknown ingestion time, levels drawn before 4 hours, or modified/extended-release products; in those situations N-acetylcysteine is given empirically with serial transaminase and acetaminophen monitoring.

Two established N-acetylcysteine regimens are used. The intravenous 21-hour (Prescott) regimen gives 150 mg/kg as a loading dose, then 50 mg/kg over the next 4 hours, then 100 mg/kg over the following 16 hours.[4] The oral 72-hour regimen gives a 140 mg/kg loading dose, then 70 mg/kg every 4 hours for 17 doses.[5] Treatment is most effective when started within 8 hours of ingestion, but is still given later, and in established liver injury or acute liver failure, where it improves outcomes. Massive or late-presenting overdose may require extended or increased dosing. This is reference information, not a treatment protocol; overdose is a medical emergency managed by clinicians and poison control.

Combination products and the 325 mg limit

[edit | edit source]

Because acetaminophen is present in many products at once -- prescription opioid combinations (e.g. hydrocodone/acetaminophen, oxycodone/acetaminophen) and over-the- counter cold, flu, and sleep products -- people can exceed the maximum daily dose without realizing it by stacking several acetaminophen-containing products, a leading route to unintentional hepatotoxicity. In January 2011 the FDA acted on this risk for PRESCRIPTION acetaminophen products: it asked manufacturers to limit acetaminophen to 325 mg per dosage unit in prescription combination products (a change manufacturers completed by 2014), and it required a boxed warning on all prescription products containing acetaminophen highlighting the potential for severe liver injury.[6] Over-the-counter acetaminophen products instead carry a Drug Facts "Liver warning," not a boxed warning. Checking every product label for acetaminophen (sometimes abbreviated APAP) and summing the total is the practical safeguard.

References

[edit | edit source]
  1. 1.0 1.1 1.2 FDA OTC Monograph for acetaminophen-containing products, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021450s015lbl.pdf
  2. Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics. 1975;55(6):871-876.
  3. Wallace CI, Dargan PI, Jones AL. Paracetamol overdose: an evidence based flowchart to guide management. Emerg Med J. 2002;19(3):202-205.
  4. Prescott LF, Illingworth RN, Critchley JA, et al. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. Br Med J. 1979;2(6198):1097-1100.
  5. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. N Engl J Med. 1988;319(24):1557-1562.
  6. U.S. Food and Drug Administration. Drug Safety Communication: Prescription acetaminophen products to be limited to 325 mg per dosage unit; boxed warning will highlight potential for severe liver failure. January 13, 2011.